Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Observational
SUMMARY
Objective: To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
• Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
• Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
• Age ≥ 18 years
Locations
Other Locations
Netherlands
Erasmus MC
RECRUITING
Rotterdam
Contact Information
Primary
Steven HJ Nagtegaal, MD PhD
s.nagtegaal@erasmusmc.nl
+31(0)107042249
Backup
Alejandra Mendez Romero, MD PhD
a.mendezromero@erasmusmc.nl
+31(0)107035829
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2025-11-01
Participants
Target number of participants: 320
Treatments
Proton group
Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro Clinic and UMC Groningen.
Photon group
Patients with grade 2 and 3 IDHmt glioma treated with photon therapy in Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC locatie VUmc Site, Verbeeten Institute, Maastro Clinic, UMC Groningen, and Leuven University Hospital.
Related Therapeutic Areas
Sponsors
Collaborators: University Medical Center Groningen, HollandPTC, Institute Verbeeten, Universitaire Ziekenhuizen KU Leuven, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Maastro Clinic, The Netherlands, Medical Center Haaglanden, Leiden University Medical Center
Leads: Erasmus Medical Center